

ARTICLE

Received 17 Sep 2012 | Accepted 15 Mar 2013 | Published 23 Apr 2013

DOI: 10.1038/ncomms2745

# Magnetic barcode assay for genetic detection of pathogens

Monty Liong<sup>1,\*</sup>, Anh N. Hoang<sup>2,\*</sup>, Jaehoon Chung<sup>1</sup>, Nil Gural<sup>2</sup>, Christopher B. Ford<sup>3</sup>, Changwook Min<sup>1</sup>, Rupal R. Shah<sup>3</sup>, Rushdy Ahmad<sup>4</sup>, Marta Fernandez-Suarez<sup>2,3,†</sup>, Sarah M. Fortune<sup>3</sup>, Mehmet Toner<sup>2</sup>, Hakho Lee<sup>1</sup> & Ralph Weissleder<sup>1,5</sup>

The task of rapidly identifying patients infected with *Mycobacterium tuberculosis* in resource-constrained environments remains a challenge. A sensitive and robust platform that does not require bacterial isolation or culture is critical in making informed diagnostic and therapeutic decisions. Here we introduce a platform for the detection of nucleic acids based on a magnetic barcoding strategy. PCR-amplified mycobacterial genes are sequence-specifically captured on microspheres, labelled by magnetic nanoprobe and detected by nuclear magnetic resonance. All components are integrated into a single, small fluidic cartridge for streamlined on-chip operation. We use this platform to detect *M. tuberculosis* and identify drug-resistance strains from mechanically processed sputum samples within 2.5 h. The specificity of the assay is confirmed by detecting a panel of clinically relevant non-*M. tuberculosis* bacteria, and the clinical utility is demonstrated by the measurements in *M. tuberculosis*-positive patient specimens. Combined with portable systems, the magnetic barcode assay holds promise to become a sensitive, high-throughput and low-cost platform for point-of-care diagnostics.

<sup>1</sup>Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. <sup>2</sup>BioMEMS Resource Center, Surgical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. <sup>3</sup>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA. <sup>4</sup>Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. <sup>5</sup>Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02114, USA. \* These authors contributed equally to this work. † Present address: Daktari Diagnostics, 85 Bolton Street, Cambridge, Massachusetts 02139, USA. Correspondence and requests for materials should be addressed to H.L. (email: hlee@mgh.harvard.edu) or to R.W. (email: rweissleder@mgh.harvard.edu).

Recent advances in genomic profiling have ushered in new opportunities in the diagnosis and treatment of human diseases. Genetic testing has a potential to enable and hasten early disease detection and rationalize treatments, especially in cancer, cardiovascular and infectious diseases<sup>1–4</sup>. One of the emerging areas of such genetic diagnoses is the detection of tuberculosis (TB). TB is a significant public health threat and economic burden. In 2011, an estimated 8.7 million TB cases were developed with 1.4 million deaths worldwide<sup>5,6</sup>. Despite the availability of efficient treatment, controlling the spread of TB remains a challenging task, primarily because of the lack of fast and sensitive detection technology<sup>7–9</sup>. The overall sensitivity of smear microscopy, the most common method for TB diagnosis, is <60%, especially in patients with low bacterial counts (<10,000 ml<sup>-1</sup> sputum) or with extrapulmonary disease; bacteria culture is the gold standard in TB detection for its highest sensitivity, but requires weeks to obtain results. Delayed case detection is associated with reduced cure rates and provides opportunity for continued transmission, which became even more a serious problem with the co-infections of HIV and the emergence of highly drug-resistant TB<sup>10,11</sup>. Developing a platform for fast, earlier and improved TB detection is thus considered crucial for efficient TB control.

Several new TB diagnostic tests have recently been introduced, based on different detection techniques (for example, Gen-Probe RNA test, interferon-gamma assay and urine-based antigen test)<sup>12,13</sup>. Nucleic acid amplification tests, in particular, have emerged as a preferred approach for TB detection. The method employs the PCR to amplify a target gene of *Mycobacterium tuberculosis* (MTB), and thereby enabling high-detection specificity and versatility. The line probe assay, for instance, colorimetrically detects multi-drug-resistant strains from PCR-amplified MTB DNA<sup>14</sup>. Most recently, GeneXpert MTB/rifampin (RIF) (Cepheid) advanced nucleic acid-based detection by integrating PCR and a highly sensitive molecular beacon assay into a single, automated system. Using chemically treated sputum samples, the system detects the presence of MTB as well as RIF-resistance<sup>15</sup>. Implementation of this test, however, is not likely to be feasible in resource-limited and field settings<sup>12</sup>, as the system operation requires the use of sophisticated optics, stable electrical power supply and routine maintenance.

We herein report on the development of a nucleic acid platform designed to provide fast and portable detection, and demonstrate the utility by detecting MTB DNA from mechanically processed TB patient sputum samples. The method is based on a magnetic barcoding strategy: PCR-amplified target MTB genes are captured and magnetically labelled by a pair of complementary oligonucleotides conjugated to microspheres and magnetic nanoprobe (MNPs). Combined with portable nuclear magnetic resonance (NMR) systems<sup>16–18</sup>, the assay showed higher sensitivity than smear microscopy, required significantly less time (<2.5 h) than culture methods, and successfully discriminated single-nucleotide polymorphism in target genes, providing facile identification of drug-resistant MTB strains.

## Results


**Magnetic barcode platform for MTB detection.** Figure 1a illustrates the magnetic barcode assay, designed to detect mycobacterial nucleic acids. In the current prototype, sputum samples are first processed off-chip to extract DNA from MTB. We adopted a simple mechanical method based on vigorous mixing with glass beads. Following the DNA extraction, the target DNA region is amplified through PCR. The amplicons are captured on polymeric beads (diameter: 1  $\mu$ m) modified with complementary capture DNAs. Subsequently, the beads are

rendered superparamagnetic by coupling MNPs (30 nm) to the opposite end of the amplicon. This scheme enhances detection specificity through the simultaneous tagging by the capture and the probe DNAs; it also offers fast binding kinetics (<1 min) as the labelling is performed in a small sample volume. The magnetic nanoparticles contain iron oxide cores encased by heat-resistant crosslinked dextran shells, to ensure high stability in varying salt conditions and the required nucleotide-annealing temperatures. After removing excess MNPs, samples are subject to NMR measurements. MNP-loaded beads produce local magnetic fields, which lead to faster relaxation of the <sup>1</sup>H NMR signal. The decay rate is proportional to the MNP concentration (and thus initial DNA), enabling quantification of target DNAs.

To streamline the assay procedure, we developed a microfluidic device for on-chip magnetic barcode assay (Fig. 1b). The device performs key functions of the assay: PCR amplification, magnetic labelling and NMR measurements (Supplementary Fig. S1). The assay uses sputum samples that are mechanically liquefied and loaded into the on-chip PCR chambers along with PCR reagents. MNPs and buffer solutions are loaded into separate chambers gated by valves. After target DNA sequences are PCR-amplified, the PCR products are combined with capture beads. The bead-DNA mixture and MNPs are then introduced into the extended mixing channel. The MNPs would only bind to the capture beads in the presence of the target amplicons. The MNP-labelled beads are purified by an in-line membrane filter (Fig. 1c) and concentrated into the miniaturized NMR ( $\mu$ NMR) chamber for detection (see Methods for detailed fluidic operations). Custom-designed portable NMR electronics are used to monitor and compensate for temperature drifts, which enables robust measurements across different temperature environments (4–50 °C)<sup>17</sup>.

**Assay optimization.** We first optimized the assay protocol to maximize the magnetic signal. Samples were prepared using synthetic 92-nucleotide (nt) single-stranded DNA (ssDNA) specifically found within the acyl-CoA dehydrogenase *fadE15* gene of MTB<sup>19,20</sup>. Non-complementary 92-nt ssDNA was used for control samples. The transverse relaxation rate ( $R_2$ ) of samples was measured, and the magnetic signal was defined as  $R_2$  ratio between the target and the control samples (see Methods for details). When ssDNA and double-stranded DNA samples were compared (Supplementary Fig. S2a), ssDNA displayed higher signal; double-stranded DNA required additional denaturing and annealing steps, which lowered the binding stability of capture beads and MNP probes. For the ssDNA samples, the highest signal could be obtained when the target ssDNA was first captured by beads and then labelled with MNPs; this approach presumably minimized competitive binding to ssDNA between capture beads and MNPs<sup>21</sup>. Based on these results, we adopted the asymmetric PCR and sequential labelling strategy for target DNA production and its magnetic targeting, respectively.

The assay conditions for sequential labelling were further refined (Supplementary Fig. S2b). Four different sizes of capture beads ranging from 0.5 to 5  $\mu$ m were tested to determine the most efficient substrate for DNA capture. After the capture beads were incubated in the ssDNA solution and labelled with MNPs, NMR measurements were performed under the same weight concentration for each bead size. The 1- $\mu$ m capture beads provided not only large surface area for capturing and magnetic labelling but also had the lowest nonspecific binding, which resulted in the highest magnetic signal. The optimal incubation temperature was  $\sim$ 37 °C, agreeing with the melting temperature




**Figure 1 | Magnetic barcode assay for sensitive TB detection. (a)** Assay procedure. From unprocessed sputum specimen, DNA is extracted through an off-chip mechanical stressing. Extracted DNA samples are then loaded into a fluidic device for on-chip processing. The target DNA sequences are amplified by asymmetric PCR and captured by polymer beads modified with capture DNA. MNPs are then used to specifically coat the beads via complementary sequence, and the samples are subjected to NMR measurements. The MNP-labelled beads accelerate the decay of NMR signal, providing analytical signal for nucleic acid detection. The entire assay time is  $\sim 2.5$  h. **(b)** A fluidic cartridge was developed to streamline the assay. The device integrates PCR chambers, mixing channels and a microcoil for NMR measurements. The entire system was designed as a disposable unit to prevent cross-contamination of PCR-amplified products. Whole-genomic DNA, extracted from expectorated samples, capture beads and MNPs are loaded into inlet chambers gated by screw valves. After on-chip PCR, magnetic labelling of the beads takes place along the mixing channel. The magnetically barcoded beads are then purified and concentrated into the  $\mu$ NMR probe (microcoil) by the membrane filter. Scale bar, 1 cm. **(c)** Scanning electron microscopy confirmed the bead capture by the membrane filter. Scale bar,  $1\ \mu\text{m}$ . Transmission electron microscopy revealed that beads are efficiently labelled with MNPs (inset). Scale bar, 30 nm.

( $t_m = 45^\circ\text{C}$ ) of 92-nt *fadE15* amplicons estimated by hairpin analysis<sup>22</sup>. With each MNP conjugated with  $> 50$  probe strands, the magnetic labelling of beads could be completed in  $< 1$  min, benefiting from the multiple binding valency of MNPs.

The developed assay protocol was applied to detect 92-nt segment of *fadE15* ssDNA (Fig. 2a). Fluorescence imaging showed strong co-localization of the near-infrared fluorescent MNPs with green-fluorescent capture beads (Fig. 2b). Flow-cytometry analysis further showed highly specific MNP labelling on beads only in the presence of target ssDNA (Fig. 2c). On-chip  $\mu$ NMR measurements confirmed the specific detection of the target ssDNA (Fig. 2d) with similar signal-to-noise ratio as in flow cytometry. Note that the  $\mu$ NMR required much lower number of beads:  $\sim 10^6$  beads in  $1\ \mu\text{l}$  volume compared with  $\sim 10^9$  beads in  $250\ \mu\text{l}$  volume for flow cytometry. The sequence-specific hybridization between oligonucleotides further enabled highly selective amplification of MNP loading onto the bead surface, offering versatility in magnetic labelling. For example, by applying a pair of MNPs conjugated with complementary oligonucleotide sequences, we could form multiple MNP layers and thus amplified particle loading onto beads (Fig. 2e, left). The resulting NMR signal for target samples increased by nearly threefold, whereas control samples showed negligible increase in identically treated beads using non-complementary ssDNA (Fig. 2e, right).

**Detection sensitivity and specificity.** The sensitivity of the magnetic barcode platform was comprehensively characterized using samples in different formats. We first used serially diluted *fadE15* ssDNA samples, and determined the absolute detection limit of the magnetic barcode assay; without the PCR amplification step, the detection limit was  $\sim 1$  nM ssDNA in  $1\ \mu\text{l}$  sample volume (Fig. 3). We next loaded genomic MTB DNA into the device, amplified the 92-nt segment of *fadE15* via asymmetric PCR and performed the magnetic barcode assay. With PCR amplification of the target gene, the system could detect down to 1–5 genomic DNA in buffer solution (Fig. 4a), demonstrating the potential to detect a single bacterium.

To evaluate the overall detection sensitivity, we used sputum samples spiked with live MTB. To mimic clinical cases, we varied the final MTB concentration up to  $10^7$  colony forming unit (CFU)  $\text{ml}^{-1}$ . Genomic DNA was first released off-chip through the mechanical disruption, and divided into two aliquots. The first half was used for conventional real-time PCR (Fig. 3b). The other half was processed by the magnetic barcode device; after the asymmetric PCR of 92-nt *fadE15*, we introduced capture beads into the PCR chamber to capture the amplicons, and then magnetically labelled the beads along the microfluidic channel. Titration measurements established that the detection limit was  $\sim 10^3$  spiked MTB in 1 ml sputum (Fig. 4b). The observed




**Figure 2 | Assay optimization and amplification process.** (a) A segment (92-nt) of *fadE15* ssDNA was used as a detection target. Capture beads and MNPs were conjugated with complementary oligonucleotides. (b) Following on-chip labelling, confocal microscopy of the magnetically barcoded beads were performed. The fluorescent polystyrene beads (green) co-localized with the near-IR fluorescence of the MNPs (red) in the presence of target *fadE15* ssDNA. Scale bar, 5 μm. (c) Measurements by flow cytometry confirmed target-specific labelling of the beads. Non-complementary ssDNA samples showed low signal close to that of control. (d) Corresponding μNMR detection also displayed strong signal with the presence of *fadE15* amplicons. (e) Sequential layering of the capture beads was performed using MNPs conjugated to alternating oligonucleotide sequences. Such layering amplified the number of MNP probes on the bead surface and therefore increased the overall magnetic signal. The error bars in **d** and **e** represent the s.d. of three replicates ( $n=3$ ).

sensitivity was lower than with pure genomic DNA samples. This could be attributed to suboptimal DNA extraction with spiked samples. Additional sample loss presumably happened during the off-chip DNA extraction and transfer processes. The current magnetic barcoding assay, however, was superior to smear test (detection threshold  $\sim 10^4$  CFU in 1 ml of sputum) and was considerably faster (2.5 h) than culture-based method that requires weeks<sup>23,24</sup>. To improve the sensitivity, we intend to combine the mechanical extraction process with chemical treatment and DNA purification. Note that the barcode assay also showed a good correlation with separate real-time PCR of whole-genomic extracts (Fig. 3b).


Signals from sputum samples containing high concentration ( $10^6$  CFU ml<sup>-1</sup>) of clinically relevant non-MTB species (*Streptococcus*

*pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Escherichia coli* and *Haemophilus influenzae*) were nearly identical to those from control sputa (Fig. 4c), indicating that nonspecific amplification and/or binding of the primers was negligible. Such high specificity would be crucial to achieve accurate MTB detection from complex specimens, which may contain multiple bacterial strains.

**TB detection in clinical samples.** To evaluate the clinical utility of the magnetic barcode platform, we analysed clinical sputum samples from MTB smear-positive patients, and as a negative control, sputa from healthy patients without a diagnosis of MTB infection. The magnetic barcode assay detected the presence of



**Figure 3 | Titration assay and PCR characterization of MTB genomic DNA.** (a) The detection sensitivity of the magnetic barcode assay without PCR amplification was determined. Samples containing 92-nt *fadE15* ssDNA were serially diluted and magnetically labelled. The detection limit was  $\sim 1$  nM of ssDNA in 1  $\mu$ l sample volume. The error bars in **a** represent the s.d. of three replicates ( $n = 3$ ). (b) Real-time PCR was used to correlate the amount of genomic DNA and to determine the detection sensitivity. Number of genomic copies was estimated using mass calculation, assuming molecular weight of 660 per base pair and MTB genome size of 4411529. Serial dilution of genomic DNA sample was performed to establish reverse transcription-PCR standard. Separate genomic DNA dilution was performed to contain 1, 10, 25, 100 and 1000 genome, and Ct values of the samples were compared with the standard. The sample dilution was used for  $\mu$ NMR measurements.



**Figure 4 | MTB detection sensitivity using the magnetic barcode assay.** (a) The detection limit of the platform with PCR steps was established. Genomic MTB DNA was loaded on the fluidic chip, and the 92-nt segment of *fadE15* amplicons were prepared by asymmetric PCR. Titration experiments with initial DNA loading showed that the assay could detect down to a few genomic DNA in buffer solution. (b) Detection of MTB within sputum samples. Whole MTB cells were spiked into 0.5 ml aliquots of MTB-negative sputa to the final concentrations ranging from 0– $10^7$  CFU ml $^{-1}$ . Following the off-chip DNA extraction, samples were measured by the magnetic barcode assay. The sensitivity was  $10^2 - 10^3$  CFU ml $^{-1}$ . (c) Control samples containing non-MTB bacteria ( $10^6$  CFU ml $^{-1}$ ) spiked into the sputa were used to confirm the specificity of the primers and barcode assay. Samples measured from the non-MTB controls displayed baseline magnetic signal, similar to the blank sputa in which no MTB was present. (d) Clinical sputum specimens were analysed with the  $\mu$ NMR assay. Compared with the samples collected from MTB-positive patients, the samples collected from MTB/HIV-positive patients showed higher  $\mu$ NMR signals. MTB-negative sputa collected from healthy volunteers were used as negative controls. The error bars in **a–d** represent the s.d. from triplicate measurements.

MTB in all MTB-positive patient samples (Fig. 4d). With control samples, the signal was at the baseline level, confirming the specificity of the assay. Interestingly, the assay performed well in patients with MTB/HIV co-infection. Diagnostics for these patients remain unclear because the standard approaches often perform poorly, yet studies have shown that HIV co-infection induces greater bacterial burden by accelerating the growth of MTB<sup>11,25,26</sup>. This finding supports our measurement of a higher bacterial burden in co-infected patient sputum.


**Analysis of single-nucleotide mutation.** Drug-resistant TB strains can be detected by identifying specific genetic mutations. For instance, over 95% of RIF-resistant MTB strains have mutations within the 81-nt core region of the *rpoB* gene (Fig. 5a, top), whereas the mutation is absent in nearly all RIF-susceptible strains<sup>2</sup>. Approximately 90% of RIF-resistant MTB is also resistant to isoniazid, which makes the mutant *rpoB* gene as a potential surrogate marker for multi-drug-resistant TB<sup>27</sup>.

We set out to optimize the magnetic barcode assay for fast detection of single-nucleotide polymorphism on the segments of the *rpoB* gene. We initially focused on detecting the C-to-T mutation in codon 531 (S531L), which is the most common amino-acid substitution responsible for RIF resistance. This mutation is observed in 70% of drug-resistant strains found in the clinics<sup>14</sup>, and these strains are reported to be the most transmissible and have the highest fitness level (that is, survival under pressure)<sup>28</sup>. Two types of capture 20-nt oligonucleotide for the *rpoB* amplicons were designed, one fully complementary to wild-type (WT) strand and the other to the S531L-mutant strand. The 81-nt *rpoB* ssDNA assumed a high hairpin melting temperature at  $\sim 68^\circ\text{C}$  (ref. 22), requiring higher incubation temperature ( $60^\circ\text{C}$ ) during the magnetic labelling. With the WT-capture beads, the barcode assay universally detected *rpoB* strands regardless of their mutational status (Fig. 5a, left). Capture beads that fully complement with S531L mutation, on the other hand, were able to distinguish the specific mutation (Fig. 5a, right); magnetic signals were  $>400\%$  higher with S531L-mutant strands than with WT or other *rpoB* mutant strands (Q513E, C-to-G mutation in codon 513; H526Y, C-to-T mutation in codon 526). Interestingly, when a similar strategy was applied to the MNPs, that is, having the oligonucleotide on the MNPs match the mutant *rpoB* ssDNA, no difference in binding affinity was observed between the target mutant and other strands (Supplementary Fig. S3). It is likely that the multiple binding valency of MNPs resulted in higher binding affinity with the *rpoB* strands and prevented the discrimination of the single-nucleotide mismatch<sup>29</sup>.

Capture oligonucleotide probes were further developed to detect other *rpoB* mutations that lead to clinically relevant amino-acid substitutions, H526Y and Q513E. Unlike the case with S531L, initial 20-nt probes for H526Y and Q513E were ineffective in discriminating target mutant strands (Supplementary Fig. S4). Analysis of the *rpoB* ssDNA revealed that the binding region for the S531L capture probe contains higher G/C contents and forms stable hairpin structure ( $t_m = 80^\circ\text{C}$ ), whereas Q513E and H526Y regions have less stable hairpin structure ( $t_m = 50-60^\circ\text{C}$ ). We thus hypothesized that reducing the length of capture probes would improve the specificity to Q513E and H526Y by decreasing the thermodynamic stability for single-nucleotide mismatch binding. Indeed, when the capture sequence was reduced to 15 nt, high selectivity for corresponding mutant strands could be achieved (Supplementary Fig. S4). These probes displayed consistent, high signal-to-noise ratios ( $\sim 300\%$ ) and complemented the *fadE15* probe for comprehensive MTB analyses (Fig. 5b).

We finally tested the developed platform to detect RIF-resistant and WT strains of MTB. RIF-resistant MTB colonies were cultured





**Figure 6 | Analysis of heterogeneous strain mixture.** (a) By using the probe sequences and assay described in Supplementary Fig. S5, the 1:1 mixture of mutant S531L isolates and drug-susceptible strain ( $10^6$  CFU for each strain) could be detected by the magnetic barcode assay. All measurements are in triplicate, and the data are shown as mean  $\pm$  s.d. (b) The ratio between WT and S531L population was obtained from a. The measured ratio (WT/S531L = 56/44) was close to the expected value (50/50).

magnetic layering, respectively. Importantly, the method also detects single-gene mutations, which enables simultaneous identification of drug-resistance MTB strains. This is a significant advance from our previous approach that utilized antibody-conjugated MNPs to target bacteria (*Bacillus Calmette-Guérin* as MTB surrogate)<sup>18</sup>; the method is limited by the specificity of antibodies and unable to identify drug-resistant strains. Second, the integrated fluidic cartridge, which combines on-chip PCR and in-line NMR detection, streamlines the assay procedure as well as minimizes sample loss and contamination. The use of  $\mu$ NMR detection further simplifies the assay, as crude DNA extracts can be directly used. These are key factors that allowed fast MTB detection and mutational analyses (2.5 h) from minimally processed sputum samples. Third, the assay system is designed for ultimate applications in point-of-care clinical settings. The miniature  $\mu$ NMR electronics is capable of robust measurements in a wide range of environmental temperature<sup>17</sup>. The assay readout is numerical data ( $R_2$ ) that requires little interpretation by operators; it can be further simplified as a binary report (positive/negative) for point-of-care applications. The assay platform is affordable for routine use as well. The one-time cost for the equipment, including the sputum processing and readout systems, is about US\$4,300, and the assay cost is under US\$3 for a fluidic device and chemical reagents (Supplementary Note 1).

The magnetic barcode platform is a versatile technology that could be readily applied to other studies and diseases. By changing the probe sequences, it could be a first-response tool to detect pathogens in hospital-acquired infections, food chains and biodefense. The system could also be a bedside tool to identify genetic mutations in chronic diseases, including cancer, heart diseases and diabetes. As an example, we applied the platform to detect the single-point mutation in exon 21 of epidermal growth factor receptor (Supplementary Fig. S6), which has clinical implications in lung cancer<sup>32</sup>. The barcoding strategy is not limited to magnetic readout, but can be extended to luminescent and plasmonic readouts using quantum dots and gold nanoprobe, respectively<sup>33</sup>. Indeed, these methods can be used to simultaneously probe multiple target strands with the arrayed colours of quantum dots and surface-enhanced Raman dyes (Supplementary Fig. S7)<sup>34</sup>.

The current prototype is being further improved for more robust operation in resource-limited settings. Most important, we are developing a fluidic device for an initial sample processing. Based on inertial focusing and chemical extraction<sup>35,36</sup>, this device is designed to allow direct, high-throughput DNA extraction from sputum samples, replacing the current mechanical setup. We envision the ultimate integration of DNA extraction and detection into a single chip, to provide one-step TB detection. Such a system will further minimize assay time, potentially enabling TB diagnosis and treatment decision at a single visit. Other areas of improvements include the use of loop-mediated isothermal amplification and replication protein A to increase the amplicon yield as well as eliminate the temperature cycling steps<sup>37,38</sup>, and combining the electronics with a wireless device would enable efficient data storage and sharing between central laboratories and remote clinics for real-time disease control. With these features, the magnetic barcode assay would then be a truly enabling technology for point-of-care diagnostics.

## Methods

**Device fabrication.** Microfluidic devices were fabricated in polydimethylsiloxane (PDMS) (Dow Corning) using soft lithography<sup>39</sup>. As a channel mould, we patterned two layers of epoxy-based SU8-3050 photoresist (Microchem) on silicon wafers using conventional photolithography. The channel patterns were cast into a 1-mm thick PDMS layer. Separately, we prepared a PDMS block embedded with a microcoil and a membrane filter (400 nm, Nuclepore; Whatman)<sup>18</sup>. The coil block and torque-actuated valves (bolt-nut pairs)<sup>40</sup> were then glued at designated areas on the cured 1-mm PDMS layer, and another 3-mm thick PDMS was poured on the assembly. After curing, fluidic ports were punched out, and the final PDMS layer was irreversibly bonded to a glass slide.

**Synthesis of capture beads and MNPs.** All oligonucleotides were purchased from Integrated DNA Technologies. The list of oligonucleotides used in the experiments are summarized in Supplementary Methods. To prepare the capture beads, 500  $\mu$ g streptavidin-coated polystyrene microbeads (1  $\mu$ m,  $8 \times 10^8$  beads; Spherotech) were incubated in 50  $\mu$ l Tris-B (20 mM Tris, pH 7.5, 1 M NaCl, 1 mM EDTA and 0.0005% Triton X-100) containing biotinylated capture DNA (1 nmol) for 30 min at room temperature and then purified. Crosslinked dextran-coated iron oxide particles (CLIO-47) were used for the magnetic labelling of beads. These particles are approximately 30 nm in hydrodynamic diameter (3 nm iron oxide core) and have an  $R_2$  relaxivity value of  $70 \text{ mM}^{-1}[\text{Fe}] \text{ s}^{-1}$ . The synthesis of amine-terminated probes and their conjugation with fluorescent molecules (fluorescein isothiocyanate, AF568 and VT680) were both done using a previously described protocol<sup>41</sup>. Each fluorescent conjugate had 5–8 dye molecules as well as 90 amine groups for further conjugation. To attach oligonucleotides to the probe, MNPs (0.25 mg) were first mixed with sulfo-SMCC (180  $\mu$ g) in 0.625 ml PBS solution (pH 7.2) for 3 h. Meanwhile, thiol-modified oligonucleotides (40 nmol) were mixed with dithiothreitol (0.1 M) in 100  $\mu$ l PBS (1 mM EDTA, pH 8) for 2 h. The reduced oligonucleotides were then purified using a NAP-5 column (GE Healthcare), with deionized water as the eluent solution. Absorbance measurements were used to determine the fractions containing the reduced oligonucleotides and the bicinchoninic protein assay solution (Thermo Fisher Scientific) was used to determine the fractions containing dithiothreitol. MNP-SMCCs were subsequently purified using membrane filtration (MWCO 30,000; Millipore Amicon) and Sephadex G-50 (GE Healthcare) with PBS as the eluent buffer. The purified maleimide-activated MNPs were eventually mixed with the reduced oligonucleotides in 2 ml PBS solution (pH 7.2) and the reaction proceeded overnight at room temperature. After this incubation, the conjugates were purified using membrane filtration (MWCO 100,000; Millipore Amicon) and Sephadex G-100 with PBS as the eluent buffer. Conjugation with 6-carboxyfluorescein-modified oligonucleotides was used to confirm that approximately 50 oligonucleotides were conjugated to each MNP.

**Bacteria culture.** The risk of infection by MTB is significantly higher for workers handling live bacteria. Infections are typically caused by the production of aerosols containing MTB. Therefore, safety precautions in the handling of MTB inside the Biosafety Level (BSL) 3 laboratories should combine administrative controls, containment principles, laboratory practices, safety equipment and proper facilities. Protective clothing, gloves, eye protection and respiratory protection are required for all experiments inside the BSL 3 laboratories. MTB isolates/strains H37Rv were grown under standard growth conditions at 37 °C with shaking to an optical density (OD) = 1.0 in Middlebrook 7H9 broth supplemented with oleic acid, albumin, dextrose, catalase (BBL Middlebrook OADC Enrichment), 0.0005% Tween 80 and 0.2% glycerol. RIF-resistant strains were prepared using clinical W-Beijing strains. Twenty independent cultures were grown in 7H9 broth

supplemented with OADC, 0.05% Tween 80 and 0.5% glycerol. Cultures were grown at 37 °C to an OD = 1.2. These independent cultures were plated onto 7H10 plates supplemented with OADC, 0.05% Tween 80, 0.5% glycerol and 2 µg ml<sup>-1</sup> of RIF. After 28 days of incubation at 37 °C, mutants were randomly selected and analysed via PCRs (forward primer: TCGGGAGCTGATCCAAAACCA; reverse primer: ACGTCCATGTAGTCCACCTCAGA). PCR products were purified and sequenced via Sanger sequencing methods. Sequencing data revealed specific nucleotide mutations in the *rpoB* region, the gene encoding for RNA polymerase subunit B. Specific mutants were chosen from each strain for further experiments.

**Clinical specimens.** The patient sputum samples were collected in Dar Es Salaam, Tanzania, under a grant from the Bill and Melinda Gates Foundation as part of Grand Challenge 13. The study was approved by the Harvard School of Public Health, and the Broad Institute of Harvard and MIT Institutional Review Board (IRB Protocol No. 18877-102). Subjects had a persistent cough for 2–3 weeks and a confirmed diagnosis of TB based on positive smear microscopy and culture results. Within a BSL 3 laboratory setting, the specimens were mechanically processed as described above to release the genomic DNA. The samples were then aliquoted into a 96-well plate to be baked at 80 °C to ensure the safety of handling. A volume of 10 µl of the sample was used for PCR amplification. The PCR amplification and sample measurements of the processed samples followed similar procedure as described above. The handling of these specimens followed all necessary safety precautions inside the BSL 3 laboratory.

**PCR for DNA amplification.** MTB were resuspended in PBS and the concentration was determined by measuring the sample OD. These bacteria were spiked into 0.5 ml aliquots of MTB-negative discarded sputum samples to a final concentration of 0–10<sup>7</sup> CFU ml<sup>-1</sup>. Genomic DNA was mechanically released by adding 250 µl of glass beads (0.1 mm diameter) and stressing the sample with FastPrep-24 Instrument (MP Biomedicals) at 50 s pulse with three intervals. Samples were incubated on ice between intervals. The samples then underwent heat treatment to ensure the safety of handling. In a typical PCR reaction, each chamber on the device contained: 0.4 µM of primers, 25 µl of PCR Mastermix (Promega, 400 µM dNTP, 3 mM MgCl<sub>2</sub> and Taq DNA polymerase) and 1–10 µl of spiked sputum (mechanically stressed). PCR-grade water was used to bring the reaction volume to 50 µl. PCR conditions were maintained at 95 °C for 10 min before initiation of 50 cycles: denaturing (95 °C for 30 s), annealing (60 °C for 30 s) and extending (72 °C for 30 s). *fadE15* Primer-1 and *fadE15* Primer-2 were used for the identification of MTB; *rpoB* Primer-1 and *rpoB* Primer-2 were used for the identification of RIF resistance. Primer-1/Primer-2 at a ratio of 10:1 ratio was used for the asymmetric PCR reaction to produce excess single-stranded oligonucleotide (ssDNA) products.

**On-chip magnetic barcoding assay.** During the PCR step, all of the valves were closed. After completion of PCR step, 1 µg capture beads (1.6 × 10<sup>6</sup> beads) were mixed with the 50 µl PCR product mixture for 3 min (37 °C for *fadE15* assays; 60 °C for *rpoB* assays). The buffer inlet containing complete PBS (CPBS; 1 × PBS with 1% FBS and 2% BSA) was opened, and the channels were filled with CPBS by pulling from the syringe pump on the outlet. After opening the inlet valves containing the capture beads, PCR product mixture and the MNPs (50 µl, 20 µg ml<sup>-1</sup>), the syringe pump on the outlet was pulled again to mix the reagents. The microbeads were captured and purified on the membrane filter. The buffer inlet was filled with more CPBS to complete the washing process. Following the washing, the flow was gently reversed (10 µl min<sup>-1</sup>) to release the beads from the membrane filter.

Changes in the transverse relaxation rate ( $\Delta R_2$ ) were measured using a  $\mu$ NMR electronics<sup>16</sup>. The sample volume per measurement was 1 µl. Carr–Purcell–Meiboom–Gill pulse sequences with the following parameters were used; echo time, 4 ms; repetition time, 6 s; the number of 180° pulses per scan, 500; and the number of scans, 8. All measurements were performed in triplicate, and the data are presented as mean ± s.e. The measured  $\Delta R_2$  value is proportional to the number of MNPs per bead. The NMR signal was obtained from  $\Delta R_2 = \Delta R_2^{\text{sample}} / \Delta R_2^{\text{control}}$ , where  $\Delta R_2^{\text{sample}}$  and  $\Delta R_2^{\text{control}}$  are the relaxation rates for the target sample and control samples, respectively. Flow-cytometry measurements were performed using a BD LSR II flow cytometer, and the mean fluorescence intensity was determined using FlowJo software.

## References

- Gazdar, A. F. Personalized medicine and inhibition of EGFR signaling in lung cancer. *N. Engl. J. Med.* **361**, 1018–1020 (2009).
- Musser, J. M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. *Clin. Microbiol. Rev.* **8**, 496–514 (1995).
- Easley, C. J. K. & Karlinsey, J. M. *et al.* A fully integrated microfluidic genetic analysis system with sample-in–answer-out capability. *Proc. Natl Acad. Sci. USA* **103**, 19272–19277 (2006).
- Kaigala, G. V. *et al.* Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients. *Electrophoresis* **27**, 3753–3763 (2006).
- WHO. *Global tuberculosis control: WHO Report 2012* (WHO, Geneva, 2012).
- Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. *Nature* **469**, 483–490 (2011).
- Halse, T. A. *et al.* Combined real-Time PCR and *rpoB* gene pyrosequencing for rapid identification of *Mycobacterium tuberculosis* and determination of rifampin resistance directly in clinical specimens. *J. Clin. Microbiol.* **48**, 1182–1188 (2010).
- Lonroth, K., Thuong, L. M., Linh, P. D. & Diwan, V. K. Delay and discontinuity—a survey of TB patients search of a diagnosis in a diversified health care system. *Int. J. Tuberc. Lung Dis.* **3**, 992–1000 (1999).
- Storla, D. G., Yimer, S. & Bjune, G. A. A systematic review of delay in the diagnosis and treatment of tuberculosis. *BMC Pub. Health* **8**, 15 (2008).
- Keshavjee, S. & Farmer, P. E. Tuberculosis, drug resistance, and the history of modern medicine. *N. Engl. J. Med.* **367**, 931–936 (2012).
- Pawlowski, A., Jansson, M., Sköld, M., Rottenberg, M. E. & Källeni, G. Tuberculosis and HIV co-infection. *PLoS Pathog.* **8**, e1002464 (2012).
- McNerney, R. & Daley, P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. *Nat. Rev. Micro.* **9**, 204–213 (2011).
- O’Sullivan, C. E., Miller, D. R., Schneider, P. S. & Roberts, G. D. Evaluation of Gen-Probe amplified *Mycobacterium tuberculosis* direct test by using respiratory and nonrespiratory specimens in a tertiary care center laboratory. *J. Clin. Microbiol.* **40**, 1723–1727 (2002).
- Barnard, M., Albert, H., Coetzee, G., O’Brien, R. & Bosman, M. E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. *Am. J. Respir. Crit. Care Med.* **177**, 787–792 (2008).
- Banada, P. P. *et al.* Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. *J. Clin. Microbiol.* **48**, 3551–3557 (2010).
- Haun, J. B. *et al.* Micro-NMR for rapid molecular analysis of human tumor samples. *Sci. Transl. Med.* **3**, 71ra16 (2011).
- Issadore, D. *et al.* Miniature magnetic resonance system for point-of-care diagnostics. *Lab Chip* **11**, 2282–2287 (2011).
- Lee, H., Yoon, T.-J. & Weissleder, R. Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system. *Angew. Chem. Int. Ed.* **48**, 5657–5660 (2009).
- Manganelli, R., Dubnau, E., Tyagi, S., Kramer, F. R. & Smith, I. Differential expression of 10 sigma factor genes in *Mycobacterium tuberculosis*. *Mol. Microbiol.* **31**, 715–724 (1999).
- Muñoz-Elías, E. J. *et al.* Replication dynamics of *Mycobacterium tuberculosis* in chronically infected mice. *Infect. Immun.* **73**, 546–551 (2005).
- Deng, H. *et al.* Gold nanoparticles with asymmetric polymerase chain reaction for colorimetric detection of DNA sequence. *Anal. Chem.* **84**, 1253–1258 (2012).
- Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* **31**, 3406–3415 (2003).
- Palomino, J. C., Martin, A., Von Groll, A. & Portaels, F. Rapid culture-based methods for drug-resistance detection in *Mycobacterium tuberculosis*. *J. Microbiol. Meth.* **75**, 161–166 (2008).
- Schluger, N. W. & Rom, W. N. Current approaches to the diagnosis of active pulmonary tuberculosis. *Am. J. Respir. Crit. Care Med.* **149**, 264–267 (1994).
- Diedrich, C. R. *et al.* Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. *PLoS One* **5**, e9611 (2010).
- Pathak, S., Wentzel-Larsen, T. & Åsjö, B. Effects of *in vitro* HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages. *Infect. Immun.* **78**, 4022–4032 (2010).
- Morgan, M., Kalantri, S., Flores, L. & Pa, M. A commercial line probe assay for the rapid detection of rifampicin resistance in *Mycobacterium tuberculosis*: a systematic review and meta-analysis. *BMC Infect. Dis.* **5**, 62–74 (2005).
- Gagneux, S. *et al.* The competitive cost of antibiotic resistance in *Mycobacterium tuberculosis*. *Science* **312**, 1944–1946 (2006).
- Liong, M., Tassa, C., Shaw, S. Y., Lee, H. & Weissleder, R. Multiplexed magnetic labelling amplification using oligonucleotide hybridization. *Adv. Mater.* **23**, H254–H257 (2011).
- Ford, C. B. *et al.* Use of whole genome sequencing to estimate the mutation rate of *Mycobacterium tuberculosis* during latent infection. *Nat. Genet.* **43**, 482–486 (2011).
- Dressman, D., Yan, H., Traverso, G., Kinzler, K. W. & Vogelstein, B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. *Proc. Natl. Acad. Sci. USA* **100**, 8817–8822 (2003).
- Dufort, S., Richard, M.-J., Lantuejoul, S. & de Fraipont, F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. *J. Exp. Clin. Cancer Res.* **30**, 57–63 (2011).
- Hill, H. D. & Mirkin, C. A. The bio-barcode assay for the detection of protein and nucleic acid targets using DTT-induced ligand exchange. *Nat. Protocols* **1**, 324–336 (2006).



34. Goddard, G. *et al.* High-resolution spectral analysis of individual SERS-active nanoparticles in flow. *J. Am. Chem. Soc.* **132**, 6081–6090 (2010).
35. Aldous, W. K., Pounder, J. I., Cloud, J. L. & Woods, G. L. Comparison of six methods of extracting *Mycobacterium tuberculosis* DNA from processed sputum for testing by quantitative real-time PCR. *J. Clin. Microbiol.* **43**, 2471–2473 (2005).
36. Di Carlo, D., Irimia, D., Tompkins, R. G. & Toner, M. Continuous inertial focusing, ordering, and separation of particles in microchannels. *Proc. Natl. Acad. Sci. USA* **104**, 18892–18897 (2007).
37. Fang, X. *et al.* A portable and integrated nucleic acid amplification microfluidic chip for identifying bacteria. *Lab Chip* **12**, 1495–1499 (2012).
38. Zou, Y., Liu, Y., Wu, X. & Shell, S. M. Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. *J. Cell. Physiol.* **208**, 267–273 (2006).
39. Xia, Y. & Whitesides, G. M. Soft lithography. *Angew. Chem. Int. Ed.* **37**, 550–575 (1998).
40. Weibel, D. B. *et al.* Torque-actuated valves for microfluidics. *Anal. Chem.* **77**, 4726–4733 (2005).
41. Pittet, M. J., Swirski, F. K., Reynolds, F., Josephson, L. & Weissleder, R. Labelling of immune cells for *in vivo* imaging using magnetofluorescent nanoparticles. *Nat. Protocols* **1**, 73–79 (2006).

### Acknowledgements

We thank I. Bagayev, J. C. Carlson, H. J. Chung, H. Im, M. McKee, N. Sergeev, H. Shao and J. Song for their assistance with experiments, and W. R. Rodriguez for helpful discussions on point-of-care diagnostic. The patient sputum samples were collected in Dar Es Salaam, Tanzania, under a grant from the Bill and Melinda Gates Foundation as

part of Grand Challenge 13. This work was supported in part by NIBIB grants R01-EB010011 (R.W.), R01-EB00462605A1 (R.W.), R01-HL113156 (H.L.), P41 EB002503 (M.T.), NHLBI contract HHSN268201000044C (R.W.), NIH grant T32CA79443 (R.W.), United States Army Medical Research Acquisition Activity Grant W81XWH-10-2-0161 (S.M.F.), NIH grant DP2 0D001378 (S.M.F.), NIAID contract U19 AI076217 (S.M.F) and the Massachusetts General Hospital Executive Committee on Research Fellowship (A.N.H and M.F.-S.).

### Author contributions

M.L. and A.N.H. conceptualized the research, assisted the device developments and performed the experiments. J.C., C.M. and H.L. conceptualized the device developments. N.G., C.B.F., R.R.S., R.A. and M.F.-S. assisted with the experiments. S.M.F., M.T., H.L. and R.W. supervised the research. M.L., A.N.H., S.M.F., M.T., H.L. and R.W. wrote the manuscript.

### Additional information

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Liang, M. *et al.* Magnetic barcode assay for genetic detection of pathogens. *Nat. Commun.* **4**:1752 doi: 10.1038/ncomms2745 (2013).